Key result
CRISPR/Cas9 knock-out of MTTP and SAR1B in Caco-2/TC7 cells successfully modeled FHBL-SD1 and FHBL-SD3, demonstrating impaired lipid droplet formation and significantly reduced lipid secretion.
Why the study?
Current treatments fail to normalize serum vitamin E levels and fully prevent severe neuro-ophthalmic complications in FHBL-SD1 and FHBL-SD3, prompting the development of cell models to explore these persistent complications.
CRISPR/Cas9-engineered Caco-2/TC7 cell models successfully replicate the defective lipid and vitamin E secretion seen in familial genetic hypobetalipoproteinemias, providing a tool for therapeutic testing.
Abetalipoproteinemia (FHBL-SD1) and chylomicron retention disease (FHBL-SD3) are rare recessive disorders of lipoprotein metabolism due to mutations in MTTP and SAR1B genes, respectively, which lead to defective chylomicron formation and secretion. This results in lipid and fat-soluble vitamin malabsorption, which induces severe neuro-ophthalmic complications. Currently, treatment combines a low-fat diet with high-dose vitamin A and E supplementation but still fails in normalizing serum vitamin E levels and providing complete ophthalmic protection. To explore these persistent complications, we developed two knock-out cell models of FHBL-SD1 and FHBL-SD3 using the CRISPR/Cas9 technique in Caco-2/TC7 cells. DNA sequencing, RNA quantification and Western blotting confirmed the introduction of mutations with protein knock-out in four clones associated with i) impaired lipid droplet formation and ii) defective triglyceride (−57.0 ± 2.6% to −83.9 ± 1.6%) and cholesterol (−35.3 ± 4.4% to −60.6 ± 3.5%) secretion. A significant decrease in α-tocopherol secretion was also observed in these clones (−41.5 ± 3.7% to −97.2 ± 2.8%), even with the pharmaceutical forms of vitamin E: tocopherol-acetate and tocofersolan (α-tocopheryl polyethylene glycol succinate 1000). MTTP silencing led to a more severe phenotype than SAR1B silencing, which is consistent with clinical observations. Our cellular models thus provide an efficient tool to experiment with therapeutic strategies and will allow progress in understanding the mechanisms involved in lipid metabolism.
No takes yet. Share an insight, caveat, or question.
Bordat et al. (2023) studied Abetalipoproteinemia (FHBL-SD1) and chylomicron retention disease (FHBL-SD3). MTTP and SAR1B gene knock-out using CRISPR/Cas9 vs. Wild-type cells was evaluated on Triglyceride, cholesterol, and α-tocopherol secretion. CRISPR/Cas9 knock-out of MTTP and SAR1B in Caco-2/TC7 cells successfully modeled FHBL-SD1 and FHBL-SD3, demonstrating impaired lipid droplet formation and significantly reduced lipid secretion.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: